The science behind the company

Ermium Therapeutics is based on the recently published , breakthrough finding of Dr Jean-Philippe Herbeuval’s team at CNRS and University of Paris. They discovered that the well-known G protein-coupled receptor (GPCR) chemokine receptor, CXCR4, acts as a master regulator of inflammation via a novel mechanism of action.

A Novel Master Regulator

This novel mechanism of action, in contrast to classical CXCR4 antagonists, allows to control efficiently the production of type 1 interferons by plasmacytoid dendritic cells (pDC) known to play a central and upstream role in the inflammatory cascade.


First chemical series generation, and proof of concept in several auto-immune disease animal models of auto-immune diseases have opened the door to the discovery of a brand-new class of drugs to be developed by Ermium.

Competitive advantages

1. Potency

Ability to potently downmodulate type I interferons and other key inflammatory cytokines.

2. Modularity

Modulation of a panel of key immune cells expressing CXCR4, including pDC.

3. Selectivity

CXCR4 expression is nearly exclusively expressed by immune cells.

4. ​Oral administration

A key property for drug candidates aimed to be used in chronic diseases.

Legal notices

Ermium Therapeutics registered under number SIRET 85199803900016, is a simplified stock company.

Located at 16 Boulevard Saint Germain 75005 PARIS and with a registered capital of €1,352, it specializes in research and development in biotechnology (7211Z).

Intellectual property :

This site constitutes a work protected by copyright in force in France. In addition, unless otherwise stated, the intellectual property rights in the documents contained in the site (texts, photographs, images, etc.) and each of the elements created for this site are the exclusive property of Ermium Therapeutics. Reproduction of all elements published on the site Ermium.com is expressly prohibited (article 122.4 of the code of the intellectual property).

Sites linked directly or indirectly to the Ermium.com site are not under its control. Consequently, Ermium Therapeutics assumes no responsibility for the information published on these sites.

Hosting

OVH:
SAS with capital of €10,069,020
RCS Lille Métropole 424,761,419,00045
APE Code 2620Z
VAT number: FR 22 424 761 419
Headquarters: 2 rue Kellermann – 59100 Roubaix – France

Publication Director :
Joel Crouzet

contact@ermium.com

Stages de couture

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Ateliers du dimanche

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Cours enfant

Abordez la fabrication d’ouvrages définis au préalable afin d’aborder les techniques de base d’assemblage

Cours réalisation 

Abordez la fabrication d’ouvrages définis au préalable afin d’aborder les techniques de base d’assemblage

Cours coupe

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.

Préparation au C.A.P.

Découvrez les bases du patronage, de la coupe à plat et de la couture sur-mesure.